1. Introduction {#sec1-pharmaceutics-11-00311}
===============

Skin aging is a progressive and comprehensive process driven by the environment and time. It is associated with aesthetic and functional changes, such as an increase in wrinkles and cutis laxa. Skin aging is a slow and irreversible process. Photoaging occurs due to perennial exposure to ultraviolet light (UV), which causes skin damage \[[@B1-pharmaceutics-11-00311]\]. Long-term UV irradiation induces reactive oxygen species (ROS) generation. Oxygen free radicals destroy DNA, the extracellular matrix and membrane lipids of skin cells and cause the development of wrinkles \[[@B2-pharmaceutics-11-00311]\]. In addition, cellular damage (e.g., DNA damage due to ROS generation) induces skin cells to overexpress matrix metalloproteinases, which destroy the skin matrix tissue \[[@B3-pharmaceutics-11-00311],[@B4-pharmaceutics-11-00311]\]. Histological studies have shown that major damage occurs in skin connective tissue upon UV irradiation \[[@B5-pharmaceutics-11-00311]\].

Vitamin D~3~ (VD~3~) is known for its capacity to maintain bone health. VD~3~ has an impact on the skin, although it is produced in the skin. Recent studies have shown that VD~3~ could repair skin cell damage caused by UV. The main damage by UV is to the DNA by the induction of cyclobutane pyrimidine dimers (CPDs) \[[@B6-pharmaceutics-11-00311],[@B7-pharmaceutics-11-00311]\]. VD~3~ significantly reduces the induction of CPDs through increasing two nucleotide excision repair by inducing expression of damage-specific DNA binding protein 2 and xeroderma pigmentosum complementation group C \[[@B8-pharmaceutics-11-00311]\]. In addition, VD~3~ increases the expression of p53 protein, which enhances DNA repair by blocking the progression of the cell cycle \[[@B9-pharmaceutics-11-00311],[@B10-pharmaceutics-11-00311]\]. UV also induces an increased level of ROS and NO in skin cells, which increases oxidative damages, such as DNA strand breaks, oxidation of purine or pyrimidine, and lipid peroxidation. VD~3~ could reduce ROS and NO generation induced by UV. Furthermore, it protects keratinocytes against UV damage \[[@B10-pharmaceutics-11-00311],[@B11-pharmaceutics-11-00311],[@B12-pharmaceutics-11-00311],[@B13-pharmaceutics-11-00311]\]. The idea of sunburn and VD~3~ preventing photoaging may seem counter-intuitive, however, skin exposed to UV is the major mechanism to obtain VD~3~ for humans. But the VD~3~ photosynthesis, erythema, and CPD formation are all in the same spectral range of UVB. Therefore, the photosynthesis of VD~3~ can not be dissociated from photodamage. Although VD~3~ could be transformed under UV, it only occurs in the first few minutes upon exposure to UV, and longer exposure adds nothing to VD~3~ stores despite increasing DNA damage in a linear fashion. So, naturally occurring VD~3~ under UV is insufficient to prevent photoaging. Additional VD~3~ needs to be supplied for skin protection \[[@B14-pharmaceutics-11-00311]\].

Photostability and effectiveness are two key parameters of sunscreen products \[[@B2-pharmaceutics-11-00311]\]. Although VD~3~ effectively prevents skin photoaging, VD~3~ is sensitive to air, light and high temperature, which is not conducive to storage, transportation and use \[[@B2-pharmaceutics-11-00311]\].VD~3~ also rapidly degrades in the traditional carrier (water/ethanol) \[[@B15-pharmaceutics-11-00311]\]. Liposomes are commonly used as a carrier to protect drugs from degradation. Liposomes are also used as a protective carrier in cosmetics to enhance the stability of active substances \[[@B16-pharmaceutics-11-00311]\]. The poor solubility of VD~3~ impedes uniform distribution in the skin. Liposomes also could improve solubility and control drug release \[[@B17-pharmaceutics-11-00311]\].

In this study, we optimized the liposomal formulation of VD~3~ to improve encapsulation efficiency (EE%) and to enhance transdermal absorption and stability of VD~3~.

2. Materials and Methods {#sec2-pharmaceutics-11-00311}
========================

2.1. Materials {#sec2dot1-pharmaceutics-11-00311}
--------------

Vitamin D~3~ (crystalline, purity \> 99%) was purchased from Shanghai Yuanye Bio-Technology Co., Ltd. (Shanghai, China). Egg phosphatidylcholine (egg PC) was purchased from Jinban Pharmaceutical Co., Ltd. (Shanghai, China). Cholesterol (Chol) was obtained from Beijing Dingguo Changsheng Biotechnology Co., Ltd. (Beijing, China). Other reagents were all of the analytical grade. Aloe-gel was purchased from PERFECT Co., Ltd. (Guangdong, China).

2.2. VD~3~ Liposomes Preparation {#sec2dot2-pharmaceutics-11-00311}
--------------------------------

Particle size and EE% were used as assessment criteria to evaluate two common liposomes preparation methods of VD~3~ (ethanol injection, film dispersion-homogenization method). A mixture of 30 mg of phospholipids, 10 mg of Chol and 10 mg of VD~3~ was dissolved in 5 mL ethanol as the lipid phase.

Ethanol injection method: The lipid solution was fast injected into 200 mL phosphate buffer solution (pH 6.8, PBS) under vortex mixing for 30 s. Then ethanol was removed by rotary evaporation and the liposomes were condensed to 100 mL under 35 °C. Finally, the liposomes of VD~3~ were sonicated for 5 min with an ice-bath.

Film dispersion-homogenization method: The lipid solution was dried by rotary evaporation at 35 °C to form a film. Then, 200 mL of PBS was used to hydrate lipid and liposomes were also condensed to 100 mL. Finally, liposomes were sonicated for 5 min in an ice-bath and were subjected to high-pressure homogenization (150 MPa) three times.

2.3. Encapsulation Efficiency {#sec2dot3-pharmaceutics-11-00311}
-----------------------------

The EE% of VD~3~ was measured by filter method. Free VD~3~ was separated from liposomes by ultrafiltration centrifuge tube. Briefly, methanol was used to release and determine total VD~3~ (W~total~) in liposomes. On the other hand, an ultrafiltration centrifuge filter (cut off MW of 10 kDa) was used to separate free VD~3~ (W~free~) from liposomes. The concentrations of W~total~ and W~free~ were then measured by high-performance liquid chromatography (HPLC) method.

The concentration of VD~3~ was determined by HPLC at an absorption wavelength of 204 nm with 1 mL/min methanol as the mobile phase using a C18 reversed-phase column (4.6 × 250 mm, 5 μm).
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2.4. Characterization of VD~3~ Liposomes {#sec2dot4-pharmaceutics-11-00311}
----------------------------------------

The particle size of VD~3~ liposomes was measured by Zetasizer Nano ZS 90 from Malvern Instruments, Ltd. (Malvern, U.K.). The size was shown by intensity-weighted distribution in Gaussian mode. A JEOL, JSM-6700F field emission scanning electron microscope (SEM) (Tokyo, Japan) was used to evaluate the surface morphology of VD~3~ liposomes at 3 kV accelerating voltage. VD~3~ liposomes were directly dropped on a clean silicon slice to dry naturally at room temperature overnight.

2.5. Optimization of Liposomes Formulation {#sec2dot5-pharmaceutics-11-00311}
------------------------------------------

On basis of single-factor experiments, we chose three interrelated factors *X1* (the amount of egg PC), *X2* (the mass ratio of egg PC to Chol), and *X3* (the mass ratio of lipid to the drug) to optimize the liposomes formulation using drug EE% as an evaluation indicator. We designed 17 experiments of three-factor, three-coded level using Box-Behnken design (BBD) to obtain the optimal VD~3~ liposomes formulation. Liposomes were prepared by the ethanol injection method. The influence of factors on EE% were shown by response surface method. The factor-level table was listed in [Table 1](#pharmaceutics-11-00311-t001){ref-type="table"}. The optimal formulation of VD~3~ liposomes was calculated by fitting the equation between EE% and three factors. The optimal formulation of VD~3~ liposomes was verified three times in repetitive experiments.

2.6. Stability of VD~3~ in Liposomes {#sec2dot6-pharmaceutics-11-00311}
------------------------------------

The stability of VD~3~ liposomes was evaluated in different conditions, including variations in time elapsed, variations in temperature, light exposure and after freezing and thawing. EE% and drug-content were used to estimate the stability of VD~3~ liposomes. We prepared 100 μg/mL of VD~3~ liposomes to compare with VD~3~ solution.

Samples were placed under 4, 25 and 40 °C in darkness and evaluated after storing for 1, 3, 5, 7 or 9 days. To study the effect of light on the stability of liposomes, 4500 Lx light was used to irradiate liposomes for 10 days at 25 °C. At each sampling time (1, 3, 5, 7 or 9 days), we analyzed the evaluation index of VD~3~ liposomes to study stability. Finally, VD~3~ liposomes were measured after freezing at −70 °C and thawing at 25 °C.

2.7. Transdermal Absorption of VD~3~ Liposomes {#sec2dot7-pharmaceutics-11-00311}
----------------------------------------------

Wistar rats were fed according to the cleanliness class specifications, and 24 h free diet. Before the transdermal absorption experiment, a rat was euthanized with sodium pentobarbital and sacrificed. A piece of rat back skin was harvested without hair and after removing skin moisture with filter paper, the rats using protocol and relevant experimental procedures was approved by the Institutional Animal Care and Use Committee of Jilin University at January, 2017 (Authorization number: 201701005). The rat skin was fitted between the accept pool and supply pool of Franz diffusion pool. The corneous layer-oriented supply pool and diffusion area was 2.54 cm^2^. One ml of VD~3~ liposomes or VD~3~ solution (1 mg/mL) was evenly daubed onto the skin, while the supply pool was covered by plastic wrap. The accept pool was filled with saline solution containing 30% (*v/v*) ethanol under stirring (400 rpm) and maintained at a constant temperature of 37 °C. The device was placed in darkness. At sampling time of 0.5, 1, 2, and 4 h, we collected 1 mL receiving liquid to test the concentration of VD~3~, then replaced equivalent fresh liquid to the accept pool.

The residual VD~3~ on the skin surface was cleaned, the skin was then cut into pieces. Pieces of skin were homogenized with PBS by a high-speed homogenizer. VD~3~ within the skin homogenate solution was extracted by liquid-liquid extraction. Briefly, 200 ul skin homogenate solution was added into 1 mL methanol with vortex for 30s. And then 1 mL of hexane was added to extract VD~3~ under oscillation mixture for 2 min \[[@B18-pharmaceutics-11-00311]\]. The mixture was centrifuged at 2000 rpm for 5 min to separate supernatant fluid. The supernatant fluid containing VD~3~ was dried by nitrogen at 4 °C. Finally, the sample was dissolved in 200 μL of HPLC initial mobile phase. The skin retention of VD~3~ was measured by the HPLC method. $$Q = \left\lbrack {\sum\limits_{i = 1}^{n - 1}{{Ci} \ast V} + {~{Cn} \ast V}0} \right\rbrack/S$$

*Q*: Average cumulative penetration of VD~3~ (μg/cm^2^)

Cn: Concentration of VD~3~ at the nth hour.

Ci: Concentration of VD~3~ when the ith.

V0: Volume of the accept pool (6.50 cm^2^)

V: Volume of the sampling

S: Diffusion area

2.8. VD~3~ Liposomes for Preventing Photoaging {#sec2dot8-pharmaceutics-11-00311}
----------------------------------------------

Animal experiments were approved by the Institutional Animal Care and Use Committee of Jilin University at January, 2017 (Authorization number: 201701005). Wistar rats were fed according to the cleanliness class specifications.

Wistar rats were divided into four groups, each group contained eight rats with half female and half male. Rats were normally fed for 7 days with 24 h free diet to adapt to the environment before the experiment.

Back hair of rats in four groups was cleanly shaved in an area of about 3 × 5 cm. Ultraviolet ray was used to illuminate the exposed skin of rats to build a photoaging model. The exposed skin of rats was continuously irradiated for 1 month by 30 W of UVA and UVB ultraviolet lamp placed 30 cm above the cage, each irradiation time was 2 h every two days.

The four photoaging model groups were respectively administrated PBS, 1 mL of 100 μg/mL VD~3~ solution, VD~3~ liposomes or 1 mL of aloe-gel twice per day. The rats were continuously treated for 1 month. Apparent properties of the rats' skin were quantitatively analyzed after treatment using the skin color and scale. And then the four groups of rats were anesthetized and sacrificed to harvest the exposed target skin, the skin was fixed by 4% paraformaldehyde, embedded in paraffin. Finally, the skin tissues were stained by the H&E method to analyze the histology of epidermis, dermis, collagen fibers and elastic fibers.

2.9. Statistical Analysis {#sec2dot9-pharmaceutics-11-00311}
-------------------------

A t-test was used to analyze the statistical significance of the data. P values \< 0.05 and \< 0.01 indicate significant difference and extremely significant difference respectively. The results are shown as mean ± SD.

3. Result and Discussion {#sec3-pharmaceutics-11-00311}
========================

3.1. Preparation of VD~3~ Liposomes {#sec3dot1-pharmaceutics-11-00311}
-----------------------------------

VD~3~ was an effective skin care product to prevent photoaging as a supplement in cosmetics. But the stability of VD~3~ was an important limiting factor in practical application. VD~3~ is a highly liposoluble vitamin and can be embedded into the lipid layer leading to high encapsulation efficiency. We used liposomes as a VD~3~ delivery carrier to improve stability and treatment efficacy.

We compared two common VD~3~ liposome preparation method (ethanol injection, and film dispersion-homogenization) to investigate the particle size and EE%. The results are shown in [Table 2](#pharmaceutics-11-00311-t002){ref-type="table"}. The film dispersion-homogenizing method resulted in multivesicular liposomes, which had a relatively larger size and polydispersity index (PDI). Ethanol injection method obtained uniform size liposomes (92.5 nm, PDI = 0.085) with higher EE% for VD~3~. Finally, we chose the ethanol injection method to prepare VD~3~ liposomes in the subsequent experiments.

3.2. Optimization of VD~3~ Liposomes Formulation {#sec3dot2-pharmaceutics-11-00311}
------------------------------------------------

On basis of single factor experiments, we used three interrelated factors *X1* (the amount of egg PC), *X2* (the mass ratio of egg PC to Chol), and *X3* (the mass ratio of lipid to the drug) as dependent variates. 17 experiments were designed by Box-Behnken design to optimize the optimal formulation using EE% as a response value. Results were listed in [Table 3](#pharmaceutics-11-00311-t003){ref-type="table"} and [Table 4](#pharmaceutics-11-00311-t004){ref-type="table"} along with the statistical results of regression analysis.

The EE% ranged from 59.32% to 84.11% in the 17 experiments. We built a fitting equation between factors and EE% by regression analysis of the results. The fitting equation between EE% and three factors was: EE% = 83.48 + 0.58*X1*+ 7.35*X2*+ 1.95*X3* − 0.60*X1X2* − 4.47*X1X*3 + 0.35*X2X3* − 6.56*X1*^2^ − 4.18*X2*^2^ − 11.17*X3*^2^.

The P value of the mathematical model was \<0.0001, R-Squared = 99.5%, which implied the model was significant. The "Lack of Fit P-value" of 0.0899 implied that the model misfits with a small probability. The model was accurate and reliable, it could be used in EE% prediction. The parameters "*X2, X3, X1X*3, *X1*^2^, *X2*^2^, *X3*^2^" were significant model terms in the model, it meant that the factors and EE% were not simple linear relations. The interaction of the two factors was signified in [Figure 1](#pharmaceutics-11-00311-f001){ref-type="fig"}. There was an obvious angle between elliptical and the coordinate axis in [Figure 1](#pharmaceutics-11-00311-f001){ref-type="fig"}A, it was shown that with the two factors (*X1X3*) existed the most significant interaction. We calculated the optimal formulation was 24.55 mg of egg PC, 5.16 mg of Chol and 11.34 mg of VD~3~, the predicted EE% was 86.82%. The predicted result was verified three times; the mean EE% of VD~3~ was 86.77% and the experimental value fit with the predicted value. Optimized liposomes were characterized in [Figure 2](#pharmaceutics-11-00311-f002){ref-type="fig"}. In [Figure 2](#pharmaceutics-11-00311-f002){ref-type="fig"}A, the mean size of VD~3~ liposomes was 99.7 nm, the zeta potential was −19.1 mV. The solubility of VD~3~ was significantly improved after envelopment in liposomes. VD~3~ liposomes exhibited as a transparent solution when the concentration was at 1 mg/mL and 100 μg/mL ([Figure 2](#pharmaceutics-11-00311-f002){ref-type="fig"}B). In [Figure 2](#pharmaceutics-11-00311-f002){ref-type="fig"}C, the surface morphology of VD~3~ liposomes were uniform spheres.

3.3. The Stability of VD~3~ Liposomes {#sec3dot3-pharmaceutics-11-00311}
-------------------------------------

Stability of VD~3~ is a major matter in the commercial application. VD~3~ could be easily degraded by various environmental factors (time, temperature and light). We used liposomes to improve the stability of VD~3~. Results are shown in [Table 5](#pharmaceutics-11-00311-t005){ref-type="table"} and [Table 6](#pharmaceutics-11-00311-t006){ref-type="table"}. The VD~3~ solution was degraded by more than 20% in ethanol/water solvent at 4, 25, and 40 °C. Especially at 40 °C the content of VD~3~ reduced by more than 50% after storing 9 days. However, when the VD~3~ was encapsulated into liposomes, the EE% and content did not significantly decrease at 4 °C and 25 °C. There was about an 8.4% reduction of EE% and 9.3% decline of content when the temperature ascended to 40 °C. Particle size and PDI of VD~3~ liposomes had a tendency to increase during storage.

Stability of VD~3~ liposomes in light suggested that liposomes could protect VD~3~ from photo-degradation. As shown in [Table 6](#pharmaceutics-11-00311-t006){ref-type="table"}, the VD~3~ liposomes shown more stability with light irradiation at 4500 Lx compared to VD~3~ solution. The EE% of liposomes did not have a significant decrease after light irradiation of 9 days. The content of VD~3~ in liposomes decreased by about 5.32% compared to 48.2% of VD~3~ solution after light irradiation for 9 days. In addition, EE% and content of VD~3~ liposomes were only reduced by 0.51% and 1.18% after freezing and thawing.

3.4. Transdermal Absorption of VD~3~ {#sec3dot4-pharmaceutics-11-00311}
------------------------------------

We respectively measured the average cumulative penetration and retention of VD~3~ in the skin, the results are shown in [Table 7](#pharmaceutics-11-00311-t007){ref-type="table"}. The total skin uptake of VD~3~ solution and VD~3~ liposomes were all about 50%. Average cumulative penetration of VD~3~ solution was about 5.2 times that of VD~3~ liposomes. However, average retention of VD~3~ liposomes was 1.65 times that of the VD~3~ solution. This indicates that the VD~3~ solution easily penetrated skin tissue. VD~3~ liposomes tended to be absorbed and stranded by the skin, which might be due to the particle size of VD~3~ liposomes. It might improve the effect of VD~3~ on photoaging.

3.5. VD~3~ Liposomes to Prevent Photoaging {#sec3dot5-pharmaceutics-11-00311}
------------------------------------------

Skin photoaging referred to long-term skin damage caused by ultraviolet radiation. VD~3~ could effectively improve the situation. VD~3~ liposomes were prepared to enhance the skin retention of VD~3~ and improve the curative effect. Firstly, a photoaging model of rats was established through UV radiation. And then PBS, VD~3~ solution, VD~3~ liposomes or aloe-gel were used to treat rats, respectively. The result was shown in [Figure 3](#pharmaceutics-11-00311-f003){ref-type="fig"}. Skin premature aging, relaxation, roughness and a series of changes of morphology could be found in [Figure 3](#pharmaceutics-11-00311-f003){ref-type="fig"}A. In the treatment groups ([Figure 3](#pharmaceutics-11-00311-f003){ref-type="fig"}B--D), it could be found that skin redness, loss of luster, roughness, abnormal thickening problems were variously improved after administration of VD~3~ solution, VD~3~ liposomes or aloe-gel for 1 month. The VD~3~ liposomes had the best treatment effect based on the improvement in skin external appearance. The skin color and scale were used as evaluation indexes of VD~3~ liposome treatment effect. The skin color of rats after treatment was shown in [Figure 4](#pharmaceutics-11-00311-f004){ref-type="fig"}. The skin color of rats after treatment was significantly lower than the PBS group, except male rats in the aloe-gel group. Skin appearance of rats was counted by scale and results were listed in [Table 8](#pharmaceutics-11-00311-t008){ref-type="table"}. Male rats in the VD~3~ liposomes group and female in VD~3~ solution, VD~3~ liposomes or aloe-gel group all received an acceptable therapeutic effect. VD~3~ liposomes had a protective effect on photoaging.

The tissue sections of treated rats were stained to further study histology changes of the skin by H&E staining. The results are shown in [Figure 5](#pharmaceutics-11-00311-f005){ref-type="fig"}.

The rat skin of the control group was with complete structure and moderate thickness. The dermis had a compact structure and collagen fibers were evenly distributed along the epidermis ([Figure 5](#pharmaceutics-11-00311-f005){ref-type="fig"}A).

Photoaging model group exhibited uneven epidermis thickening, the dermis structure was disrupted with thinning, collagen fibers swelling, homogenizing, and follicle hyperplasia ([Figure 5](#pharmaceutics-11-00311-f005){ref-type="fig"}B).

The VD~3~ solution could slightly improve the structural integrity of photoaging skin, and promote the production of new collagen fibers, however the structure of the dermis was relatively loose ([Figure 5](#pharmaceutics-11-00311-f005){ref-type="fig"}C).

VD~3~ liposomes had the best treatment effect on photoaging. The VD~3~ liposomes fundamentally restored the structure of photoaging skin. The boundary between the epidermis and dermis layer was very clear. The newborn collagen fibers and glands were orderly lined with compact structures ([Figure 5](#pharmaceutics-11-00311-f005){ref-type="fig"}D). The treatment effect of VD~3~ liposomes was similar to the positive control of aloe-gel ([Figure 5](#pharmaceutics-11-00311-f005){ref-type="fig"}E).

The treatment of PBS resulted in no improvement for photoaging skin ([Figure 4](#pharmaceutics-11-00311-f004){ref-type="fig"}F). The treatment effect of VD~3~ solution, VD~3~ liposomes and aloe-gel had no obvious selectivity for gender.

4. Conclusions {#sec4-pharmaceutics-11-00311}
==============

Excessive exposure to sunlight causes skin photoaging. The severity of this complication mainly depends on genetic factors, skin type, and the area of skin exposed to the sun. The skin produces high-level ROS upon UV radiation, which damages skin cells. In addition, UV radiation might directly damage DNA and cause skin cancer.

VD~3~ was found to have a good protective effect from UV radiation and photoaging. Of course, there are still some remaining issues to be overcome, such as stability and skin uptake of VD~3~. In 1987, Christian Dior launched the first liposomes cosmetics "Capture". Since then, this class of cosmetics has received positive attention. About 300 liposomal cosmetics have been commercialized so far. In this study, we prepared VD~3~ liposomes to prevent photoaging. The VD~3~ liposomes had high drug EE% and uniform particle size. Liposomes raised the retention amount of VD~3~ in the skin by transdermal absorption compared to the VD~3~ solution. Finally, VD~3~ liposomes could significantly improve skin appearance and repair damage in the histology of photoaging. This suggests that VD~3~ liposomes warrant further research as a protective agent against photoaging in the skin care field.
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![Response surfaces and contours. (**A**) Interaction of *X1* and *X2,* (**B**) Interaction of *X1* and *X3*, (**C**) Interaction of *X2* and *X3.*](pharmaceutics-11-00311-g001){#pharmaceutics-11-00311-f001}

![Characterization of vitamin D~3~ (VD~3~) liposomes. (**A**) The particle size of VD~3~ liposomes. (**B**) Morphological appearance of VD~3~ liposomes at 1 mg/mL and 100 μg/mL. (**C**) Scanning electron microscope (SEM) of VD~3~ liposomes at secondary electron imaging mode (×30,000).](pharmaceutics-11-00311-g002){#pharmaceutics-11-00311-f002}

![The skin condition of rats after administration VD~3~ solution, VD~3~ liposomes or aloe-gel for one month. (**A**) Treatment with PBS as a control group. (**B**) Treatment with VD~3~ solution. (**C**) Treatment with VD~3~ liposomes. (**D**) Treatment with aloe-gel as a positive control group.](pharmaceutics-11-00311-g003){#pharmaceutics-11-00311-f003}

![Color of rats' skin after treatment. \* *p* \< 0.05, VD~3~ liposomes vs. VD~3~ solution for female rats; ^\#\#^ *p* \< 0.01, VD~3~ solution, VD~3~ liposomes or aloe-gel vs. PBS for male and female rats.](pharmaceutics-11-00311-g004){#pharmaceutics-11-00311-f004}

![The histology of skin by H&E staining of the skin tissue section. (**A**) Control, normal skin (**B**) Photoaging model, (**C**) Treatment with VD~3~ solution, (**D**) Treatment with VD~3~ liposomes, (**E**) Treatment with aloe-gel as positive control (**F**) Treatment with PBS. H&E 200x.](pharmaceutics-11-00311-g005){#pharmaceutics-11-00311-f005}

pharmaceutics-11-00311-t001_Table 1

###### 

Levels of factors used in Box-Behnken design (BBD).

  Factors                                                 Range and Level           
  ------------------------------------------------------- ----------------- ------- -------
  *X1* (the amount of egg phosphatidylcholine (PC))       10 mg             25 mg   40 mg
  *X2* (the mass ratio of egg PC-to-cholesterol (Chol))   1:1               3:1     5:1
  *X3* (the mass ratio of lipid-to-drug)                  1:2               2:1     3.5:1

pharmaceutics-11-00311-t002_Table 2

###### 

Effect of different VD~3~ liposomes preparation methods on the encapsulation efficiency and size distribution (*n* = 3).

  Evaluation Index                 Film Dispersion-Homogenizing   Ethanol Injection
  -------------------------------- ------------------------------ -------------------
  Encapsulation efficiency (EE%)   62.2 ± 0.9                     80.3 ± 0.4
  Particle size (nm)               169.4 ± 2.0                    92.5 ± 1.8

pharmaceutics-11-00311-t003_Table 3

###### 

The matrix of Box-Behnken design and the responding experimental results.

  Std   Run   Levels of Independent Fctors   Response EE           
  ----- ----- ------------------------------ ------------- ------- -------
  12    1     25 mg                          5:1           3.5:1   77.35
  13    2     25 mg                          3:1           2:1     83.79
  5     3     10 mg                          3:1           1:2     59.32
  9     4     25 mg                          1:1           1:2     59.61
  8     5     40 mg                          3:1           3.5:1   63.24
  4     6     40 mg                          5:1           2:1     81.04
  17    7     25 mg                          3:1           2:1     83.35
  14    8     25 mg                          3:1           2:1     83.68
  15    9     25 mg                          3:1           2:1     84.11
  10    10    25 mg                          5:1           1:2     73.15
  16    11    25 mg                          3:1           2:1     82.45
  11    12    25 mg                          1:1           3.5:1   62.39
  2     13    40 mg                          1:1           2:1     67.11
  6     14    40 mg                          3:1           1:2     67.87
  3     15    10 mg                          5:1           2:1     79.55
  7     16    10 mg                          3:1           3.5:1   72.56
  1     17    10 mg                          1:1           2:1     63.22

pharmaceutics-11-00311-t004_Table 4

###### 

Statistical results of regression analysis.

  Source        Sum of    df   Mean     F Value   P Value
  ------------- --------- ---- -------- --------- ----------
  Model         1400.43   9    155.60   154.33    \<0.0001
  *X1*          2.66      1    2.66     2.63      0.1486
  *X2*          431.59    1    431.59   428.05    \<0.0001
  *X3*          30.38     1    30.38    30.13     0.0009
  *X1X2*        1.44      1    1.44     1.43      0.2710
  *X1X3*        79.83     1    79.83    79.18     \<0.0001
  *X2X3*        0.50      1    0.50     0.50      0.5024
  *X1^2^*       181.29    1    181.29   179.8     \<0.0001
  *X2^2^*       73.72     1    73.72    73.11     \<0.0001
  *X3^2^*       525.04    1    525.04   520.73    \<0.0001
  Residual      7.06      7    1.01     \-        \-
  Lack of Fit   5.45      3    1.82     4.51      0.0899
  Pure Error    1.61      4    0.40     \-        \-
  Cor Total     1407.49   16   \-       \-        \-

pharmaceutics-11-00311-t005_Table 5

###### 

The stability of VD~3~ liposomes in different time and temperature. Polydispersity index (PDI).

  ---------------- --------------------- --------------------- -------------- -------------------
  **4 °C**         **VD~3~ Solution**    **VD~3~ Liposomes**                  
  **Day**          **Content (μg/mL)**   **Content (μg/mL)**   **EE%**        **Size (nm)/PDI**
  1                98.74 ± 1.69          96.56 ± 2.35          87.24 ± 1.07   107.7/0.11
  3                93.56 ± 1.19          96.37 ± 1.03          87.11 ± 1.40   115.4/0.18
  5                87.34 ± 1.01          95.74 ± 0.63          86.88 ± 1.65   126.2/0.15
  7                82.11 ± 1.09          95.15 ± 1.75          86.58 ± 1.39   133.0/0.25
  9                78.40 ± 1.66          94.89 ± 1.75          86.41 ± 1.37   150.9/0.33
  **25 °C**        **VD~3~ Solution**    **VD~3~ Liposomes**                  
  **Day**          **Content (μg/mL)**   **Content (μg/mL)**   **EE%**        **Size (nm)/PDI**
  1                97.27 ± 1.61          95.24 ± 0.34          86.69 ± 1.58   109.6/0.15
  3                92.08 ± 2.29          95.13 ± 1.74          86.58 ± 0.72   104.7/0.17
  5                85.46 ± 1.98          94.88 ± 0.61          85.17 ± 0.40   113.6/0.17
  7                78.31 ± 2.53          94.60 ± 0.86          85.24 ± 1.33   120.9/0.21
  9                73.36 ± 1.31          93.98 ± 1.45          85.09 ± 0.32   135.9/0.25
  **4** **0 °C**   **VD~3~ Solution**    **VD~3~ Liposomes**                  
  **Day**          **Content (μg/mL)**   **Content (μg/mL)**   **EE%**        **Size (nm)/PDI**
  1                82.40 ± 2.72          91.93 ± 0.56          82.16 ± 0.97   111.2/0.17
  3                73.44 ± 2.47          91.09 ± 0.59          81.98 ± 1.98   125.1/0.15
  5                66.97 ± 1.48          90.81 ± 0.79          81.22 ± 2.65   115.7/0.19
  7                59.38 ± 0.75          90.38 ± 1.73          80.74 ± 2.39   127.3/0.24
  9                51.17 ± 0.61          89.57 ± 0.39          79.39 ± 0.55   129.8/0.39
  ---------------- --------------------- --------------------- -------------- -------------------

pharmaceutics-11-00311-t006_Table 6

###### 

The stability of VD~3~ liposomes in 25 °C and 4500 Lx light.

  Day   VD~3~ Solution   VD~3~ Liposomes                  
  ----- ---------------- ----------------- -------------- ------------
  1     91.35 ± 0.50     96.07 ± 1.05      86.43 ± 2.76   103.1/0.17
  3     83.34 ± 1.21     95.73 ± 0.19      86.09 ± 0.46   108.6/0.19
  5     72.90 ± 1.02     95.21 ± 1.78      85.33 ± 1.39   132.6/0.16
  7     63.11 ± 2.56     95.38 ± 0.89      85.47 ± 0.26   130.9/0.23
  9     50.48 ± 2.15     93.58 ± 2.52      83.69 ± 0.62   137.3/0.27
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###### 

Average cumulative penetration and retention of VD~3~ in the skin.

  Time (h)   Average Cumulative Penetration   Run     Average Retention in Skin            
  ---------- -------------------------------- ------- --------------------------- -------- --------
  0.5        2.97                             1.14    1                           112.97   184.87
  1          26.92                            4.13    2                           116.92   178.29
  2          61.56                            8.55    3                           111.56   183.22
  4          80.29                            15.48   \-                          \-       \-
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###### 

Assessment of photographs of photoaging rats.

  Gender                   Assessment     Phosphate Buffer Solution (PBS)   VD~3~ Solution   VD~3~ Liposomes   Aloe-Gel
  ------------------------ -------------- --------------------------------- ---------------- ----------------- ----------
  Male                     Wrinkles ^a^   Na                                Na               Na                Na
  Mottles ^a^              Na             1                                 Na               1                 
  Photodamage ^a^          3              2                                 Na               Na                
  Roughness ^a^            4              3                                 3                4                 
  Overall appearance ^b^   +++++++        ++++++                            +++              +++++             
  Female                   Wrinkles ^a^   Na                                Na               Na                Na
  Mottles ^a^              Na             1                                 Na               1                 
  Photodamage ^a^          1              Na                                Na               Na                
  Roughness ^a^            3              2                                 1                1                 
  Overall appearance ^b^   ++++           +++                               \+               ++                

^a^: Based on a five-point scale: 1, excellent; 5, poor.Na: not available. ^b^: + and ++, satisfactory; +++ and ++++, acceptable; from +++++ to +++++++, poor.

[^1]: These authors contributed equally to this work.
